The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy.
Nicole Haense
No relevant relationships to disclose
Claudia Pauligk
No relevant relationships to disclose
Frederik Marme
No relevant relationships to disclose
Dominique Werner
No relevant relationships to disclose
Daniela Sorgius
No relevant relationships to disclose
Wael Hozaeel
No relevant relationships to disclose
Mohammad-Reza Rafiyan
No relevant relationships to disclose
Oliver G. Ottmann
No relevant relationships to disclose
Daniel Klunker
Employment or Leadership Position - TRION Pharma
Michael Jäger
Employment or Leadership Position - TRION Research
Elke Jäger
No relevant relationships to disclose
Horst Lindhofer
Employment or Leadership Position - TRION Pharma
Stock Ownership - TRION Pharma
Salah-Eddin Al-Batran
No relevant relationships to disclose